Breaking News, Trials & Filings

ICT Treatment Misses GBM Endpoint

Reaches PFS, but OS numbers don't separate against placebo

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

ImmunoCellular Therapeutics (ICT) posted results from its randomized, placebo-controlled Phase II trial of dendritic cell-based vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM). The vaccine demonstrated a statistically significant increase in progression-free survival (PFS), but missed its primary endpoint of overall survival (OS), which was not statistically significant compared to placebo. Median progression-free survival times were two months longer for ICT-107 ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters